Newsroom
May 4, 2020
Drs. Thomas Patterson, chief of the Division of Infectious Diseases, and Jason Bowling, Infectious Diseases, explained the implications of the FDA fast-tracking emergency authorization of the new anti-viral drug, remdesivir, as the new standard of care for hospitalized COVID-19 patients. Read and watch the full story.
May 4, 2020
President William L. Henrich, M.D., MACP, is quoted in this story about at $100,000 gift to UT Health San Antonio for COVID-19 testing by Hyundai Hope on Wheels. Read the story.
May 4, 2020
Drs. Thomas Patterson, chief of the Division of Infectious Diseases, and Jason Bowling, Infectious Diseases, explained the implications of the FDA fast-tracking emergency authorization of the new anti-viral drug, remdesivir, as the new standard of care for hospitalized COVID-19 patients. Read and watch the full story.
May 1, 2020
Dr. Barbara Taylor, Infectious Diseases, was interviewed about the preliminary results of a clinical trial studying remdesivir as an anti-viral agent against COVID-19. Watch the story.
May 1, 2020
UT Health San Antonio has begun its planning efforts for some portion of the workforce to return to campus. This effort will occur over the next several months and will occur in phases. Currently, 70 % of our workforce is successfully working from home and, for now, these individuals should continue to do so. When it is time for you to return to working on campus, you will be so informed by your supervisor.
May 1, 2020
Dr. Thomas Patterson, chief of infectious diseases and PI of the remdesivir clinical trial site locally, discusses the promising early results of the drug in the fight against COVID-19. Read the full story.